Compare Star Bulk Carriers Corp (SBLK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Star Bulk Carriers Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Star Bulk Carriers Corp trades at $30.19 (market cap $3.54B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 6.17% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Star Bulk Carriers Corp for 24 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SBLK | VRTX | |
|---|---|---|
Market Cap | $3.54B | $127.55B |
Volume | 1,437,622 | 1,487,944 |
Sector | Industrials | Health |
52-Week High | $32.49 | $557.96 |
52-Week Low | $16.79 | $407.37 |
Typical Hold Time | 24 Days | 120 Days |
Enterprise Value | $4.22B | $121.68B |
Dividend Yield | 6.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Star Bulk Carriers (SBLK) trades at $29.69, down 0.57% on the day, with a bearish technical signal despite strong fundamental performance. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $1.21 exceeding expectations by 27%. Revenue grew 45% year-over-year, and management maintains a 100% free cash flow distribution policy, recently declaring a $0.90 dividend payable September 3, 2026.
SBLK presents a compelling value opportunity with attractive valuation metrics (P/E 11.95, P/S 2.86) and strong profitability (23.87% net margin). Analyst consensus leans bullish (58% buy ratings), but technical weakness and shipping market volatility pose near-term risks. The stock's 61% annual gain reflects strong operational execution, though current price action suggests consolidation after recent highs.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
